Merck, Zealand Get CRLS for Investigational Products

The FDA delivered a couple of unwelcome holiday gifts to two hopeful sponsors in the form of Complete Response Letters (CRL) — one for Merck’s chronic cough drug gefapixant and the second for Zealand Pharma’s dasiglucagon, an investigational agent intended to treat congenital hyperinsulinism.
Source: Drug Industry Daily